AnaCardio Completes Phase 2a Enrollment for Heart Failure Drug Candidate AC01
核心洞察
AnaCardio (搜索) has completed patient enrollment in the phase 2a portion of its GOAL-HF1 clinical study evaluating AC01 in heart failure patients with reduced ejection fraction.
The randomized, double-blind, placebo-controlled study enrolled 26 patients across 13 specialized heart failure centers in Sweden, the Netherlands, Italy, and the UK.
The study aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics following 28 days of treatment, with results expected by the end of the year.
Swedish biopharmaceutical company AnaCardio (搜索) has completed patient enrollment in the phase 2a portion of its GOAL-HF1 clinical study, marking a significant milestone in the development of AC01, a novel drug candidate for heart failure with reduced ejection fraction (HFrEF). The company announced the completion of enrollment on September 16, 2025, with study results anticipated by the end of the year.
Study Design and Patient Population
The phase 2a portion of GOAL-HF1 enrolled a total of 26 patients in a randomized, double-blind, placebo-controlled design. The study is being conducted across 13 highly specialized heart failure centers spanning four countries: Sweden, the Netherlands, Italy, and the UK. This multi-national approach ensures diverse patient representation and robust data collection from leading cardiovascular care institutions.
The study protocol calls for 28 days of treatment, during which researchers will evaluate multiple parameters including safety, tolerability, pharmacokinetics, and pharmacodynamics of AC01. This comprehensive assessment approach is designed to provide crucial data for the continued development of the drug candidate.
Novel Approach to Heart Failure Treatment
AC01 represents what AnaCardio (搜索) describes as "a new approach to treating patients with heart failure and reduced ejection fraction." The drug candidate is currently being evaluated in the broader GOAL-HF1 study, which encompasses both phase 1b and phase 2a components, specifically targeting patients with HFrEF.
Heart failure with reduced ejection fraction is a serious cardiovascular condition where the heart's ability to pump blood effectively is significantly impaired. The completion of enrollment in this phase 2a study represents an important step forward in developing potential new treatment options for this patient population.
Company Background and Investment
AnaCardio (搜索) AB operates as a privately held Swedish clinical-stage biopharmaceutical company with a focused mission on developing novel drugs to treat heart failure. The company's lead asset, AC01, is the centerpiece of its current clinical development program.
The company operates as a portfolio investment of Karolinska Development (搜索) AB, which holds a 10 percent ownership stake in AnaCardio (搜索). Viktor Drvota, CEO of Karolinska Development, expressed encouragement about the milestone, stating: "We are encouraged to see our portfolio company AnaCardio successfully completing patient enrollment in its phase 2a study with the drug candidate AC01, which represents a new approach to treating patients with heart failure and reduced ejection fraction. We now look forward to the study results and the continued advancement of the program."
Next Steps and Timeline
With patient enrollment now complete, AnaCardio (搜索) will focus on completing the 28-day treatment period and analyzing the resulting data. The company has indicated that study results are expected by the end of the year, which will provide critical insights into AC01's potential as a therapeutic option for heart failure patients.
The successful completion of enrollment demonstrates AnaCardio (搜索)'s ability to execute clinical trials across multiple international sites and positions the company for the next phase of AC01's development program, pending positive results from the current study.